000			01339 a2200361 4500
005			20250517155620.0
264		0	_c20171023
008			201710s 0 0 eng d
022			_a1872-9142
024	7		_a10.1016/j.molimm.2017.05.015 _2doi
040			_aNLM _beng _cNLM
100	1		_aHawksworth, Owen A
245	0	0	_aNew concepts on the therapeutic control of complement anaphylatoxin receptors. _h[electronic resource]
260			_bMolecular immunology _c09 2017
300			_a36-43 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAntibodies, Monoclonal, Humanized _xtherapeutic use
650	0	4	_aComplement Activation _xdrug effects
650	0	4	_aComplement C3a _ximmunology
650	0	4	_aComplement C5a _ximmunology
650	0	4	_aComplement Inactivating Agents _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aInflammation _xdrug therapy
650	0	4	_aReceptor, Anaphylatoxin C5a _ximmunology
650	0	4	_aReceptors, Chemokine _ximmunology
650	0	4	_aReceptors, Complement _ximmunology
700	1		_aLi, Xaria X
700	1		_aCoulthard, Liam G
700	1		_aWolvetang, Ernst J
700	1		_aWoodruff, Trent M
773	0		_tMolecular immunology _gvol. 89 _gp. 36-43
856	4	0	_uhttps://doi.org/10.1016/j.molimm.2017.05.015 _zAvailable from publisher's website
999			_c27240994 _d27240994